Dravet Syndrome
Biogen and Stoke report positive results for Dravet syndrome drug
July 17, 2025Research and Development Biogen, Dravet Syndrome, Neurology, Stoke Therapeutics, epilepsy, rare diseases
Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which is being developed for Dravet …
UCB presents epilepsy research at American Epilepsy Society Annual Meeting
December 9, 2024Research and Development American Epilepsy Society, Dravet Syndrome, Neurology, UCB, sleep
Belgian-based biopharmaceutical company UCB has announced it will present 32 abstracts at the American Epilepsy Society (AES) Annual Meeting – …
FDA refuses to review Zogenix’s Fintepla in Dravet syndrome, shares tumble 30%
April 9, 2019Manufacturing and Production, Sales and Marketing Dravet Syndrome, FDA, Fintepla, Zogenix
California-based biopharma firm Zogenix has been left frustrated after it received a correspondence from the FDA noting its refusal to …
Latest content
Global coalition calls for stronger government action on COPD
September 18, 2026
Global health researchers call for more equitable partnerships
September 17, 2026
Liverpool launches £20m lab for infectious disease drug discovery
September 16, 2026
Circle Health Group expands into UK laboratory operations
September 15, 2026
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
September 14, 2026
